bioMérieux S.A. (BMXXY) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 18.16 means the share price is 18.16 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $10.5B is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerbioMérieux S.A. (BMXXY) trades at $8.86. bioMérieux S.A. is a global leader in in vitro diagnostics, providing solutions for infectious disease diagnosis, industrial microbiological testing, and other clinical applications. Market cap: $10.5B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for BMXXY: BMXXY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BMXXY against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
BMXXY: 2/2 scored disciplines lean bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
bioMérieux S.A. (BMXXY) Healthcare & Pipeline Overview
bioMérieux S.A. is a global in vitro diagnostics company specializing in infectious disease and industrial microbiological testing. With a focus on clinical and industrial applications, the company serves a diverse range of customers, including hospitals, laboratories, and the food, pharmaceutical, and cosmetic industries, positioning itself in a growing healthcare market.
What Is the Investment Thesis for BMXXY?
The company's diverse product portfolio and global presence provide a stable revenue base, while its focus on innovation and strategic acquisitions drive future growth. With a P/E ratio of 18.16 and a profit margin of 9.8%, bioMérieux demonstrates financial stability. Upcoming catalysts include expansion into emerging markets and development of new diagnostic solutions. Potential risks include regulatory changes and increased competition. The company's dividend yield of 0.95% offers a modest return while investors await further growth.
Based on FMP financials and quantitative analysis
BMXXY Key Highlights
Market capitalization of $10.5B, reflecting its significant presence in the in vitro diagnostics market.
- P/E ratio of 18.16, indicating investor confidence in the company's earnings potential.
- Profit margin of 9.8%, demonstrating efficient operations and profitability.
- Gross margin of 53.1%, showcasing the company's ability to maintain pricing power and manage costs effectively.
- Dividend yield of 0.95%, providing a steady income stream for investors.
Who Are BMXXY's Competitors?
BMXXY is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ALPMY Astellas Pharma Inc. | $14.55 | +2.34% | $26.1B | — |
| GIKLY Grifols, S.A. | $5.75 | 0.00% | $15.1B | — |
| GNMSF Genmab A/S | $329.25 | 0.00% | $20.2B | — |
| ORINY Orion Oyj | $46.00 | +0.51% | $25.9B | — |
| SAUHF Straumann Holding AG | $113.46 | 0.00% | $18.1B | — |
| SI SHOULDER INNOVATIONS, INC. | $19.27 | +0.84% | $400M | 365-pillar |
| QTEX Inspira Technologies Oxy B.H.N. Ltd. | $0.82 | -0.87% | $35.7M | 435-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BMXXY's Key Strengths?
Global presence and established distribution network.
- Diverse product portfolio covering a wide range of diagnostic applications.
- Strong focus on innovation and research and development.
- Reputation for high-quality products and services.
What Are BMXXY's Weaknesses?
Exposure to currency fluctuations due to international operations.
- Dependence on regulatory approvals for new products.
- Competition from larger and more diversified companies.
- Potential for product recalls or liability claims.
What Could Drive BMXXY Stock Higher?
BMXXY catalyst: Expansion into emerging markets, particularly in Asia Pacific and Latin America, is expected to drive revenue growth.
- Launch of new diagnostic solutions for emerging infectious diseases and chronic conditions in the next 1-2 years.
- Strategic acquisitions and partnerships to expand product portfolio and geographic reach.
- Increasing demand for microbiological testing in the food, pharmaceutical, and cosmetic industries.
- Integration of digital technologies, such as artificial intelligence and data analytics, into diagnostic solutions.
What Are the Key Risks for BMXXY?
Increased competition from existing and new players in the in vitro diagnostics market.
- Changes in regulatory requirements and healthcare policies could impact the company's operations and profitability.
- Economic downturns could reduce healthcare spending and demand for diagnostic solutions.
- Technological disruptions could render existing products obsolete.
- Exposure to currency fluctuations due to international operations.
What Are the Growth Opportunities for BMXXY?
- Expansion in Emerging Markets: bioMérieux has the opportunity to expand its presence in emerging markets, particularly in Asia Pacific and Latin America, where healthcare infrastructure is developing and demand for diagnostic solutions is increasing. These regions offer high growth potential due to their large populations and increasing healthcare spending. By establishing strategic partnerships and tailoring its product offerings to local needs, bioMérieux can capture a significant share of these rapidly growing markets. This expansion could contribute significantly to revenue growth over the next 3-5 years.
- Development of New Diagnostic Solutions: Investing in research and development to create innovative diagnostic solutions for emerging infectious diseases and chronic conditions represents a significant growth opportunity. By leveraging its expertise in molecular diagnostics and microbiology, bioMérieux can develop tests that offer faster, more accurate results, improving patient outcomes and driving revenue growth. Focus areas include antimicrobial resistance, respiratory infections, and personalized medicine. Successful product launches in these areas could drive revenue growth over the next 2-4 years.
- Strategic Acquisitions and Partnerships: bioMérieux can pursue strategic acquisitions and partnerships to expand its product portfolio, geographic reach, and technological capabilities. By acquiring companies with complementary technologies or market access, bioMérieux can accelerate its growth and strengthen its competitive position. Potential targets include companies specializing in point-of-care testing, digital diagnostics, and data analytics. Strategic partnerships can also provide access to new markets and technologies, driving innovation and revenue growth over the next 2-5 years.
- Focus on Industrial Microbiology: bioMérieux can capitalize on the growing demand for microbiological testing in the food, pharmaceutical, and cosmetic industries. As regulatory requirements become more stringent and consumer awareness of food safety increases, companies are investing more in quality control and testing. bioMérieux can leverage its expertise in industrial microbiology to provide comprehensive testing solutions that help companies ensure the safety and quality of their products. This focus can lead to increased revenue and market share in the industrial sector over the next 1-3 years.
- Leveraging Digital Technologies: Integrating digital technologies, such as artificial intelligence and data analytics, into its diagnostic solutions can enhance their accuracy, efficiency, and accessibility. By developing AI-powered diagnostic tools that can analyze large datasets and provide personalized insights, bioMérieux can improve patient outcomes and reduce healthcare costs. Additionally, digital platforms can facilitate remote monitoring and data sharing, improving access to diagnostic services in underserved areas. This integration can drive innovation and create new revenue streams over the next 3-5 years.
What Are BMXXY's Competitive Advantages?
- Established brand reputation and long-standing customer relationships.
- Extensive portfolio of diagnostic solutions covering a wide range of diseases and applications.
- Strong focus on innovation and research and development.
- Global presence and distribution network.
- High switching costs for customers due to regulatory requirements and validation processes.
What Does BMXXY Do?
bioMérieux S.A., founded in 1963 and headquartered in Marcy l'Etoile, France, is a global leader in the field of in vitro diagnostics. Originally known as B-D Mérieux, the company develops, manufactures, and markets diagnostic solutions used to detect and analyze infectious diseases, cardiovascular pathologies, and cancers. Its products and services cater to clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company's offerings include diagnostic systems and reagents used on biological samples, as well as microbiological testing solutions for industrial applications, primarily in the food, pharmaceutical, cosmetics, and veterinary sectors. bioMérieux operates across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. As a subsidiary of Institut Mérieux SA, bioMérieux leverages its parent company's resources and expertise to drive innovation and expand its global footprint. The company's commitment to improving public health through diagnostic solutions has solidified its position as a key player in the healthcare industry.
What Products and Services Does BMXXY Offer?
- Develops and produces in vitro diagnostic solutions.
- Offers systems for diagnosing infectious diseases.
- Provides solutions for diagnosing cardiovascular pathologies.
- Offers solutions for diagnosing various cancers.
- Provides microbiological testing for food, pharmaceutical, cosmetics, and veterinary sectors.
- Serves clinical and hospital laboratories.
- Caters to physicians and blood banks.
- Supports industrial control laboratories.
How Does BMXXY Make Money?
- Develops and manufactures in vitro diagnostic systems and reagents.
- Sells diagnostic solutions to clinical and industrial customers.
- Provides service and support for its installed base of diagnostic systems.
- Generates revenue through reagent sales, instrument placements, and service contracts.
What Industry Does BMXXY Operate In?
bioMérieux S.A. operates in the in vitro diagnostics market, a sector driven by increasing healthcare expenditure, an aging global population, and the rising prevalence of infectious diseases. The market is characterized by technological advancements, such as molecular diagnostics and point-of-care testing. bioMérieux competes with companies like ALPMY, GIKLY, GNMSF, ORINY, and SAUHF, focusing on innovation and strategic partnerships to maintain its competitive edge. The global in vitro diagnostics market is projected to continue growing, presenting significant opportunities for bioMérieux.
Who Are BMXXY's Key Customers?
- Clinical and hospital laboratories
- Physicians
- Blood banks
- Industrial control laboratories (food, pharmaceutical, cosmetics, veterinary)
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 74 days ago
- ● No analyst coverage
- ● Reported in EUR, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 20 snapshots
| 2026-08-23 | 46 |
| 2026-08-27 | 46 |
| 2026-08-31 | 46 |
| 2026-09-04 | 46 |
| 2026-09-08 | 46 |
| 2026-09-11 | 46 |
What changed?
The score has stayed at 46.
Over the same 19 days the stock moved +7.7%.
Company Profile
bioMérieux S.A. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Marcy l'Étoile, FR. The company is led by CEO Pierre Boulud. BMXXY has traded publicly since 2023.
bioMérieux S.A. Financial Trajectory
bioMérieux S.A. (BMXXY) reported $2.28B in revenue for Q2 FY2026, a decline of 2.3% compared to the prior quarter. The company recorded net income of $262.3M, with diluted EPS of $0.22. Revenue has contracted over three consecutive quarters, which investors in this large-cap Healthcare stock should monitor closely. Across the four most recent quarters, BMXXY averaged $0.20 in diluted EPS.
How bioMérieux S.A. Is Valued
bioMérieux S.A. carries a market capitalization of $10.5B, placing it in the large-cap category.
Key Financial Metrics
Return on equity for bioMérieux S.A. stands at 9.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.1%, showing how much profit it generates from its asset base. BMXXY trades at a trailing price-to-earnings ratio of 18.16, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
bioMérieux S.A.'s Piotroski F-Score is 9/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 6.32 places it in the safe zone, indicating low near-term bankruptcy risk.
BMXXY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Global presence and established distribution network.
- Diverse product portfolio covering a wide range of diagnostic applications.
- Strong focus on innovation and research and development.
- Reputation for high-quality products and services.
Bear Case
- Exposure to currency fluctuations due to international operations.
- Dependence on regulatory approvals for new products.
- Competition from larger and more diversified companies.
- Potential for product recalls or liability claims.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $2.28B | $262M | $0.22 |
| Q4 FY2025 | $2.33B | $272M | $0.23 |
| Q2 FY2025 | $2.37B | $187M | $0.16 |
| Q4 FY2024 | $2.41B | $252M | $0.21 |
Q2 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from EUR at today's rate
BMXXY Latest News
No recent news available for BMXXY.
BMXXY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BMXXY.
Price Targets
Wall Street price target analysis for BMXXY.
BMXXY MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BMXXY; grades run from A+ (80-100) to F (below 30).
Leadership: Pierre Boulud
CEO
Pierre Boulud serves as the Chief Executive Officer of bioMérieux S.A., a global leader in in vitro diagnostics. His career spans several decades in the healthcare and diagnostics industries. Prior to joining bioMérieux, Boulud held various leadership positions at major pharmaceutical and medical device companies, contributing to strategic growth and operational excellence. He brings extensive experience in global market expansion, product development, and commercialization. Boulud's expertise encompasses a deep understanding of the healthcare landscape and a commitment to innovation in diagnostics.
Track Record: Under Pierre Boulud's leadership, bioMérieux S.A. has focused on expanding its global footprint and strengthening its position in the in vitro diagnostics market. Key achievements include strategic acquisitions to enhance the company's product portfolio and technological capabilities. Boulud has also overseen the development and launch of innovative diagnostic solutions for emerging infectious diseases and chronic conditions. His strategic decisions have driven revenue growth and improved operational efficiency.
bioMérieux S.A. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. BMXXY is an ADR that allows U.S. investors to invest in bioMérieux S.A. without directly dealing with foreign stock exchanges. Each BMXXY ADR represents a specific number of bioMérieux S.A. shares traded on its home market.
- Home Market Ticker: Euronext Paris, France
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: BMXX
BMXXY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market, indicating that bioMérieux S.A. (BMXXY) has limited regulatory oversight and disclosure requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies in this tier may not meet minimum financial standards or reporting requirements, leading to increased risks for investors due to limited information availability and potential for fraud or manipulation. Trading on this tier often involves higher price volatility and lower liquidity.
- OTC Tier: OTC Other
- Limited Financial Disclosure: Lack of comprehensive and timely financial information increases investment risk.
- Lower Liquidity: Reduced trading volume and wider bid-ask spreads can lead to difficulties in buying or selling shares.
- Increased Price Volatility: The absence of stringent regulatory oversight can result in higher price swings.
- Potential for Fraud or Manipulation: The OTC Other tier has a higher risk of fraudulent activities due to less regulatory scrutiny.
- Limited Investor Protection: Fewer regulations may offer less protection to investors in case of disputes or company mismanagement.
- Verify the company's registration and legal standing.
- Investigate the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Review any available financial statements and disclosures.
- Check for any regulatory actions or legal proceedings against the company.
- Evaluate the liquidity and trading volume of the stock.
- Understand the risks associated with investing in OTC securities.
- Subsidiary of Institut Mérieux SA: Being part of a larger, established organization can provide some level of assurance.
- Global Operations: Operating in multiple countries suggests a degree of business sophistication.
- Established History: Founded in 1963, the company has a long operating history.
- Presence in Healthcare Sector: Focus on diagnostics for infectious diseases, cardiovascular pathologies, and cancers.
Common Questions About BMXXY (Healthcare)
Is BMXXY a good stock?
Stock Expert AI does not rate BMXXY buy, sell or hold. bioMérieux S.A. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does bioMérieux S.A. do?
bioMérieux S.A. specializes in in vitro diagnostics, developing and producing solutions for the diagnosis of infectious diseases, cardiovascular pathologies, and various cancers.
What are the key factors to evaluate for BMXXY?
Evaluate BMXXY on fundamentals, analyst consensus, and risk factors. P/E: 18.16x vs the S&P 500's ~20-25x. With a P/E ratio of 18.16 and a profit margin of 9.8%, bioMérieux demonstrates financial stability. Not financial advice.
How frequently does BMXXY data refresh on this page?
BMXXY's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven BMXXY's recent stock price performance?
bioMérieux S.A. (BMXXY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Global presence and established distribution network. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BMXXY overvalued or undervalued right now?
bioMérieux S.A. (BMXXY) trades at 18.16x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BMXXY?
Yes, most major brokerages offer fractional shares of bioMérieux S.A. (BMXXY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BMXXY's earnings and financial reports?
bioMérieux S.A. (BMXXY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BMXXY earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- OTC listing introduces additional risks and uncertainties.